Issue: Vol. 5, No. 14 - October 17, 2018

Table of Contents – MedTech Strategist, Vol. 5, No. 14, October 17, 2018 (44 Pages):

“From the Community Blog,” by the MedTech Strategist Team

“MD Start: Building Medtech Companies in Europe,” by David Cassak

“Regulatory Shifts for HCT/P Products Put Orthobiologics Manufacturers on the Spot,” by Wendy Diller

Sidebars:

   – “FDA’s Evolving Criteria for Tissue-based Biologics: Takeaways,” by Wendy DIller

   – “MiMedx Wins an Orthopedic Rarity: RMAT Designation for AmnioFix Injectable,” by Wendy Diller

“Three Strategies to Avoid Medical Device Commoditization,” by Tom Dudnyk, VIVO Agency

Start-Ups to Watch—”EmboMedics: Thinking Organically about Embolization,” by Colin Miller

Start-Ups to Watch—”Kobara Medical: Epicardial Pacing Provides Advantages for Heart Failure Patients,” by Mary Stuart